纳西他单抗联合治疗难治性和/或复发性高危神经母细胞瘤。

IF 0.8 4区医学 Q4 HEMATOLOGY

Journal of Pediatric Hematology/Oncology Pub Date : 2025-08-12 DOI:10.1097/MPH.0000000000003096

Erin Murphy Trovillion, Meghan Michael, Lauren Brown, Katlin Phillips, Javier Oesterheld, Giselle Saulnier-Sholler

{"title":"纳西他单抗联合治疗难治性和/或复发性高危神经母细胞瘤。","authors":"Erin Murphy Trovillion, Meghan Michael, Lauren Brown, Katlin Phillips, Javier Oesterheld, Giselle Saulnier-Sholler","doi":"10.1097/MPH.0000000000003096","DOIUrl":null,"url":null,"abstract":"Approved treatments for patients with refractory and/or relapsed (R/R) high-risk (HR) neuroblastoma are limited, and there is a need for new treatment combinations. In this case series, 4 patients were treated with the anti-GD2 monoclonal antibody naxitamab and granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with cyclophosphamide and topotecan between August 2021 and December 2022. This combined chemoimmunotherapy regimen was well tolerated in these heavily pretreated patients with R/R HR neuroblastoma who had few treatment options and overall poor prognoses.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Naxitamab-combination Therapy for the Treatment of Patients With Refractory and/or Relapsed High-risk Neuroblastoma.\",\"authors\":\"Erin Murphy Trovillion, Meghan Michael, Lauren Brown, Katlin Phillips, Javier Oesterheld, Giselle Saulnier-Sholler\",\"doi\":\"10.1097/MPH.0000000000003096\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Approved treatments for patients with refractory and/or relapsed (R/R) high-risk (HR) neuroblastoma are limited, and there is a need for new treatment combinations. In this case series, 4 patients were treated with the anti-GD2 monoclonal antibody naxitamab and granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with cyclophosphamide and topotecan between August 2021 and December 2022. This combined chemoimmunotherapy regimen was well tolerated in these heavily pretreated patients with R/R HR neuroblastoma who had few treatment options and overall poor prognoses.\",\"PeriodicalId\":16693,\"journal\":{\"name\":\"Journal of Pediatric Hematology/Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pediatric Hematology/Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MPH.0000000000003096\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Hematology/Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MPH.0000000000003096","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

对于难治性和/或复发（R/R）高风险（HR）神经母细胞瘤患者的批准治疗是有限的，并且需要新的治疗组合。在该病例系列中，4例患者在2021年8月至2022年12月期间接受抗gd2单克隆抗体纳西他单抗和粒细胞-巨噬细胞集落刺激因子（GM-CSF）联合环磷酰胺和拓扑替康治疗。这种联合化疗免疫治疗方案在这些经过大量预处理的R/R HR神经母细胞瘤患者中具有良好的耐受性，这些患者的治疗选择很少，总体预后较差。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Naxitamab-combination Therapy for the Treatment of Patients With Refractory and/or Relapsed High-risk Neuroblastoma.

Approved treatments for patients with refractory and/or relapsed (R/R) high-risk (HR) neuroblastoma are limited, and there is a need for new treatment combinations. In this case series, 4 patients were treated with the anti-GD2 monoclonal antibody naxitamab and granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with cyclophosphamide and topotecan between August 2021 and December 2022. This combined chemoimmunotherapy regimen was well tolerated in these heavily pretreated patients with R/R HR neuroblastoma who had few treatment options and overall poor prognoses.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Pediatric Hematology/Oncology 医学-小儿科

CiteScore

1.90

自引率

8.30%

发文量

415

审稿时长

2.5 months

期刊介绍： Journal of Pediatric Hematology/Oncology (JPHO) reports on major advances in the diagnosis and treatment of cancer and blood diseases in children. The journal publishes original research, commentaries, historical insights, and clinical and laboratory observations.